AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 JUL 3 - (NewsRx.com & NewsRx.net) -- GenoMed, Inc., (GMED), a St. Louis, Missouri-based medical genomics and disease-management company, announced its latest clinical trial, for osteoporosis.
GenoMed's approach uses an already-existing, safe hypertension drug: an ACE inhibitor, or an angiotensin II receptor blocker (ARB). ACE stands for "angiotensin I converting enzyme."
The treatment is designed to counteract the underlying process in osteoporosis: loss of bone through ...
Source: HighBeam Research, GenoMed announces ACE inhibitor trial for bone loss.